Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers

References

• Bai, J., et al., 2019. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: food/herb–drug interactions and structure–activity relationships. Toxicology and applied pharmacology, 369, 49–59.
   PubMed Web of Science ®Google Scholar
• Bedada, S.K., Appani, R., and Boga, P.K., 2017a. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation. Drug development and industrial pharmacy, 43 (6), 932–938.
   PubMed Web of Science ®Google Scholar
• Bedada, S.K. and Boga, P.K., 2017. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. European journal of clinical pharmacology, 73 (3), 343–349.
   PubMed Web of Science ®Google Scholar
• Bedada, S.K., Boga, P.K., and Kotakonda, H.K., 2017b. The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. Xenobiotica, 47 (3), 230–235.
   PubMed Web of Science ®Google Scholar
• Bois, F.Y., et al., 1994a. Bioequivalence: performance of several measures of extent of absorption. Pharmaceutical research, 11 (5), 715–722.
   PubMed Web of Science ®Google Scholar
• Bois, F.Y., et al., 1994b. Bioequivalence: performance of several measures of rate of absorption. Pharmaceutical research, 11 (7), 966–974.
   PubMed Web of Science ®Google Scholar
• Brambila-Tapia, A.J., 2013. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Revista de investigacion clinica, 65 (5), 445–454.
   PubMedGoogle Scholar
• Cui, J., Liu, X., and Chow, L., 2019. Flavonoids as P-gp inhibitors: a systematic review of SARs. Current medicinal chemistry, 26 (25), 4799–4831.
   PubMed Web of Science ®Google Scholar
• Cvetkovic, M., et al., 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug metabolism and disposition, 27 (8), 866–871.
   PubMed Web of Science ®Google Scholar
• Dewanjee, S., et al., 2017. Natural products as alternative choices for P-glycoprotein (P-gp) inhibition. Molecules, 22 (6), 871.
   PubMed Web of Science ®Google Scholar
• Fung, K.L. and Gottesman, M.M., 2009. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochimica et biophysica acta (BBA), 1794 (5), 860–871.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2017. Therapeutic effects of breviscapine in cardiovascular diseases: a review. Frontiers in pharmacology, 8, 289.
   PubMed Web of Science ®Google Scholar
• Han, Y., et al., 2009. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica, 39 (9), 694–699.
   PubMed Web of Science ®Google Scholar
• Han, Y.L., et al., 2014. In vitro inhibitory effects of scutellarin on six human/rat cytochrome P450 enzymes and P-glycoprotein. Molecules, 19 (5), 5748–5760.
   PubMed Web of Science ®Google Scholar
• Hao, F.F., Lai, Y., and Dong, Y., 2016. Correlation of MDR1 and SLCO1B1 gene polymorphisms with coronary heart disease in Bai population of Yunnan Province. Guangdong medical journal, 37, 1317–1321.
   Google Scholar
• Haufroid, V., et al., 2004. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 14 (3), 147–154.
   PubMedGoogle Scholar
• Hoffmeyer, S., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the national academy of sciences of the United States of America, 97 (7), 3473–3478.
   PubMed Web of Science ®Google Scholar
• Ieiri, I., Takane, H., and Otsubo, K., 2004. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clinical pharmacokinetics, 43 (9), 553–576.
   PubMed Web of Science ®Google Scholar
• Jin, G.L., Qin, H.L., and Shi, M.Q., 2015. Study of protective effects of BRE on acute cerebral ischemia injury in mice and brain tissue P-gp mRNA and protein expression relationship. Pharmacology and clinics of Chinese materia medica, 31 (1), 76–79.
   Google Scholar
• Juan, H., et al., 2007. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. European journal of clinical pharmacology, 63 (7), 663–668.
   PubMed Web of Science ®Google Scholar
• Júnior, M.A., et al., 2015. Determination of fexofenadine in Hank's balanced salt solution by high-performance liquid chromatography with ultraviolet detection: application to Caco-2 cell permeability studies. Biomedical chromatography, 29 (4), 537–544.
   PubMed Web of Science ®Google Scholar
• Kalliokoski, A. and Niemi, M., 2009. Impact of OATP transporters on pharmacokinetics. British journal of pharmacology, 158 (3), 693–705.
   PubMed Web of Science ®Google Scholar
• Kim, K.A. and Park, J.Y., 2010. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. European journal of clinical pharmacology, 66 (7), 721–725.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty, C., et al., 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315 (5811), 525–528.
   PubMed Web of Science ®Google Scholar
• Lai, Y., et al., 2011. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups. Die pharmazie, 66 (2), 136–140.
   PubMed Web of Science ®Google Scholar
• Lin, Y.Z., et al., 2016. Effect of breviscapine against hepatic ischemia reperfusion injury. Journal of surgical research, 203 (2), 268–274.
   PubMed Web of Science ®Google Scholar
• Liu, R., Jin, L., and Gou, X.L., 2015. Effect of scutellarin on the expression and activity of P-gp in Caco-2 cells. China pharmacist, 18, 529–532.
   Google Scholar
• Lu, C., et al., 2017. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomedicine & pharmacotherapy = biomedecine & pharmacotherapie, 86, 450–456.
   PubMed Web of Science ®Google Scholar
• Neerati, P. and Bedada, S.K., 2015. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacological reports: PR, 67 (2), 339–344.
   PubMed Web of Science ®Google Scholar
• Niemi, M., 2007. Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 8 (7), 787–802.
   PubMed Web of Science ®Google Scholar
• Niemi, M., et al., 2005. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). British journal of clinical pharmacology, 59 (5), 602–604.
   PubMed Web of Science ®Google Scholar
• Okyar, A., et al., 2012. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiology international, 29 (4), 443–453.
   PubMed Web of Science ®Google Scholar
• Pasanen, M.K., Neuvonen, P.J., and Niemi, M., 2008. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics, 9 (1), 19–33.
   PubMed Web of Science ®Google Scholar
• Siegmund, W., et al., 2002. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clinical pharmacology & therapeutics, 72 (5), 572–583.
   PubMed Web of Science ®Google Scholar
• Skalski, D., et al., 2017. Associations between MDR1 C3435T polymorphism and drug-resistant epilepsy in the Polish population. Acta neurologica belgica, 117 (1), 153–158.
   PubMed Web of Science ®Google Scholar
• Tirona, R.G., et al., 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. The journal of biological chemistry, 276 (38), 35669–35675.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. 2012. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Rockville, MD: Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry.
   Google Scholar
• Yamada, S., et al., 2009. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Therapeutic drug monitoring, 31 (6), 764–768.
   PubMed Web of Science ®Google Scholar
• Yamasaki, Y., et al., 2018. Characterization of P-glycoprotein humanized mice generated by chromosome engineering technology: its utility for prediction of drug distribution to the brain in humans. Drug metabolism and disposition, 46 (11), 1756–1766.
   PubMed Web of Science ®Google Scholar
• Yi, S.Y., et al., 2004. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clinical pharmacology and therapeutics, 76 (5), 418–427.
   PubMed Web of Science ®Google Scholar
• Yu, L., et al., 2013. In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs. Journal of ethnopharmacology, 150 (2), 485–491.
   PubMed Web of Science ®Google Scholar
• Yulan, S. and Fang, F., 2006. Sensitive liquid chromatography–tandem mass spectrometry method for the determination of scutellarin in human plasma: application to a pharmacokinetic study. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 830 (1), 1–5.
   PubMed Web of Science ®Google Scholar
• Zhang, W.X., et al., 2005. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clinica chimica acta, 359 (1–2), 46–52.
   PubMed Web of Science ®Google Scholar
• Zhou, X., et al., 2018. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. European journal of clinical pharmacology, 74 (1), 37–44.
   PubMed Web of Science ®Google Scholar
• Zhou, S., Lim, L.Y., and Chowbay, B., 2004. Herbal modulation of P-glycoprotein. Drug metabolism reviews, 36 (1), 57–104.
   PubMed Web of Science ®Google Scholar
• Zhou, Q., et al., 2013. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. Journal of ethnopharmacology, 146 (3), 744–749.
   PubMed Web of Science ®Google Scholar